Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

538 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease.
Siemers E, Feaster T, Sethuraman G, Sundell K, Skljarevski V, Cline EN, Zhang H, Jerecic J, Honig LS, Salloway S, Sperling R, Trame MN, Dodds MG, Johnson K. Siemers E, et al. Among authors: salloway s. J Prev Alzheimers Dis. 2025 Jan;12(1):100005. doi: 10.1016/j.tjpad.2024.100005. Epub 2025 Jan 1. J Prev Alzheimers Dis. 2025. PMID: 39800458 Free article. Clinical Trial.
Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.
Rabinovici GD, Knopman DS, Arbizu J, Benzinger TLS, Donohoe KJ, Hansson O, Herscovitch P, Kuo PH, Lingler JH, Minoshima S, Murray ME, Price JC, Salloway SP, Weber CJ, Carrillo MC, Johnson KA. Rabinovici GD, et al. Among authors: salloway sp. J Nucl Med. 2025 Jan 8:jnumed.124.268756. doi: 10.2967/jnumed.124.268756. Online ahead of print. J Nucl Med. 2025. PMID: 39778970
Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.
Rabinovici GD, Knopman DS, Arbizu J, Benzinger TLS, Donohoe KJ, Hansson O, Herscovitch P, Kuo PH, Lingler JH, Minoshima S, Murray ME, Price JC, Salloway SP, Weber CJ, Carrillo MC, Johnson KA. Rabinovici GD, et al. Among authors: salloway sp. Alzheimers Dement. 2025 Jan 8. doi: 10.1002/alz.14338. Online ahead of print. Alzheimers Dement. 2025. PMID: 39776249 Review.
Robust, fully-automated assessment of cerebral perivascular spaces and white matter lesions: a multicentre MRI longitudinal study of their evolution and association with risk of dementia and accelerated brain atrophy.
Barisano G, Iv M, Choupan J, Hayden-Gephart M; Alzheimer’s Disease Neuroimaging Initiative. Barisano G, et al. EBioMedicine. 2025 Jan;111:105523. doi: 10.1016/j.ebiom.2024.105523. Epub 2024 Dec 24. EBioMedicine. 2025. PMID: 39721217 Free PMC article.
Longitudinal cognitive performance of participants with sporadic early onset Alzheimer's disease from LEADS.
Hammers DB, Eloyan A, Taurone A, Thangarajah M, Gao S, Beckett L, Polsinelli AJ, Kirby K, Dage JL, Nudelman K, Aisen P, Reman R, La Joie R, Lagarde J, Atri A, Clark D, Day GS, Duara R, Graff-Radford NR, Grant I, Honig LS, Johnson ECB, Jones DT, Masdeu JC, Mendez MF, Womack K, Musiek E, Onyike CU, Riddle M, Rogalski E, Salloway S, Sha SJ, Turner RS, Wingo TS, Wolk DA, Carrillo MC, Rabinovici GD, Dickerson BC, Apostolova LG; LEADS Consortium. Hammers DB, et al. Among authors: salloway s. Alzheimers Dement. 2024 Dec 23. doi: 10.1002/alz.14439. Online ahead of print. Alzheimers Dement. 2024. PMID: 39713873
Differences in baseline cognitive performance between participants with early-onset and late-onset Alzheimer's disease: Comparison of LEADS and ADNI.
Hammers DB, Eloyan A, Thangarajah M, Taurone A, Beckett L, Gao S, Polsinelli AJ, Kirby K, Dage JL, Nudelman K, Aisen P, Reman R, La Joie R, Lagarde J, Atri A, Clark D, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu JC, Mendez MF, Womack K, Musiek E, Onyike CU, Riddle M, Grant I, Rogalski E, Johnson ECB, Salloway S, Sha SJ, Turner RS, Wingo TS, Wolk DA, Carrillo MC, Dickerson BC, Rabinovici GD, Apostolova LG; LEADS Consortium 1 for the Alzheimer's Disease Neuroimaging Initiative. Hammers DB, et al. Among authors: salloway s. Alzheimers Dement. 2024 Dec 23. doi: 10.1002/alz.14218. Online ahead of print. Alzheimers Dement. 2024. PMID: 39711228
The POINTER Imaging baseline cohort: Associations between multimodal neuroimaging biomarkers, cardiovascular health, and cognition.
Harrison TM, Ward T, Taggett J, Maillard P, Lockhart SN, Jung Y, Lovato LC, Koeppe R, Jagust WJ, Harvey D, Masdeu JC, Oh H, Gitelman DR, Aggarwal NT, Espeland MA, Cleveland ML, Whitmer R, Farias ST, Salloway S, Pavlik V, Yu M, Tangney C, Snyder H, Carrillo M, Baker LD, Vemuri P, DeCarli C, Landau SM; U.S. POINTER Study Group. Harrison TM, et al. Among authors: salloway s. Alzheimers Dement. 2024 Dec 6. doi: 10.1002/alz.14399. Online ahead of print. Alzheimers Dement. 2024. PMID: 39641363
Comparative neurofilament light chain trajectories in CSF and plasma in autosomal dominant Alzheimer's disease.
Hofmann A, Häsler LM, Lambert M, Kaeser SA, Gräber-Sultan S, Obermüller U, Kuder-Buletta E, la Fougere C, Laske C, Vöglein J, Levin J, Fox NC, Ryan NS, Zetterberg H, Llibre-Guerra JJ, Perrin RJ, Ibanez L, Schofield PR, Brooks WS, Day GS, Farlow MR, Allegri RF, Chrem Mendez P, Ikeuchi T, Kasuga K, Lee JH, Roh JH, Mori H, Lopera F, Bateman RJ, McDade E, Gordon BA, Chhatwal JP, Jucker M, Schultz SA; Dominantly Inherited Alzheimer Network. Hofmann A, et al. Nat Commun. 2024 Nov 18;15(1):9982. doi: 10.1038/s41467-024-52937-8. Nat Commun. 2024. PMID: 39557867 Free PMC article.
538 results